In a patient with chronic obstructive pulmonary disease who is on chronic oral corticosteroids and has a normal eosinophil count, is biologic therapy indicated?

Biologic Therapy in COPD with Chronic Steroid Use and Normal Eosinophils

Biologic therapy IS indicated for COPD patients on chronic oral corticosteroids even with normal eosinophil counts, as chronic steroid dependence itself represents a severe, treatment-refractory phenotype that may benefit from steroid-sparing biologics.

Primary Recommendation

The presence of chronic oral corticosteroid (OCS) dependence in COPD is a critical indicator for considering biologic therapy, independent of eosinophil levels. Real-world evidence demonstrates that OCS-dependent COPD patients treated with anti-IL5/IL5R biologics achieved a 78% reduction in daily steroid dose and 88% reduction in annual exacerbations, even when residual eosinophilia was present despite chronic steroid use 1. This suggests that chronic steroids may suppress eosinophil counts while type-2 inflammation persists.

Clinical Algorithm for Decision-Making

Step 1: Confirm Eligibility Criteria

Your patient must meet these requirements:

• On triple inhaled therapy (LAMA/LABA/ICS) with continued exacerbations 2
• Chronic OCS dependence (maintenance oral steroids)
• History of frequent exacerbations (≥2 moderate or ≥1 severe per year)
• FEV1/FVC ratio typically reduced with more severe airflow limitation 3

Step 2: Consider Biologic Options

Dupilumab and mepolizumab have shown efficacy in COPD:

• Dupilumab reduced annual exacerbations and improved quality of life scores 4
• Mepolizumab showed benefits in reducing exacerbations 4
• Both demonstrated steroid-sparing effects in OCS-dependent patients 5, 1

Step 3: Address the Eosinophil Paradox

The normal eosinophil count in your patient does not exclude biologic therapy for several critical reasons:

• Blood eosinophils are suppressed by chronic OCS use, creating a false-negative biomarker 1
• In the real-world case series, 5 of 6 OCS-dependent COPD patients had residual eosinophilia (mean 237 cells/μL) despite chronic steroids, yet all responded to anti-IL5 therapy 1
• Blood eosinophils poorly predict sputum eosinophilia and are unstable 6
• OCS dependence itself may be a more relevant phenotypic marker than eosinophil count in this population

Evidence Strength and Nuances

The 2023 Canadian Thoracic Society guidelines recommend against chronic systemic oral corticosteroids for COPD maintenance 2, yet many patients remain OCS-dependent in practice. This creates a clinical imperative to pursue steroid-sparing strategies.

Recent high-certainty evidence shows biologics reduce annual exacerbation rates (mean difference -0.16 exacerbations/year) and slightly reduce serious adverse events (RR 0.87) 4. The steroid-sparing benefit is particularly important given that a 42% OCS reduction translates to meaningful harm prevention for serious infections, pneumonia, and osteoporotic fractures 5.

Important Caveats

• Biologics show smaller effect sizes in COPD compared to asthma (exacerbation RR 0.78 vs 0.38) 5
• Effects on lung function and quality of life are limited 4
• Only 5.8-16.7% of hospitalized COPD patients meet current biologic eligibility criteria 3
• The main barrier is often inadequate optimization of triple inhaled therapy before considering biologics 3

Practical Implementation

Before initiating biologics, ensure:

1. Maximum optimization of triple inhaled therapy (LAMA/LABA/ICS at appropriate doses)
2. Consider adding macrolide therapy if appropriate (normal QT, no drug interactions, no mycobacterial infection) 2
3. Consider roflumilast or N-acetylcysteine for chronic bronchitic phenotype 2

If exacerbations persist despite the above AND the patient requires chronic OCS:

• Initiate biologic therapy (dupilumab or mepolizumab preferred based on evidence)
• The goal is steroid dose reduction and exacerbation prevention
• Monitor for reduction in OCS requirements over 12 months 1

The favorable safety profile (reduced serious adverse events) combined with substantial steroid-sparing effects and exacerbation reduction justifies biologic use in this high-risk, OCS-dependent population, regardless of current eosinophil count 5, 4, 1.